US gastroenterologists' familiarity and experience with Entyvio has increased

30 September 2015

A majority of surveyed US gastroenterologists are highly familiar with Entyvio (vedolizumab), with 62% reporting they have prescribed Entyvio, produced by Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502), to at least one of their ulcerative colitis (UC) or Crohn’s disease (CD) patients.

According to market research group Decision Resources, many surveyed and interviewed physicians cite Entyvio's new mechanism of action and its efficacy as a perceived advantage as lack or loss of response in patients using anti-TNF agents is a substantial concern. Although clinical data suggest weaker efficacy in CD than UC, and that the theoretical risk of PML is still a concern for many surveyed physicians, a majority of gastroenterologists indicate a high level of willingness to prescribe Entyvio for both UC and CD.

Other key findings from the LaunchTrends report titled "Entyvio Wave 3 (US)"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology